Prevenar 13 approved for pneumonia prevention in adults

The pneumococcal vaccine Prevenar 13 can now be used to prevent pneumonia in adults aged 18 years and over.

Prevenar 13 was initially licensed for the prevention of invasive disease, pneumonia and acute otitis media in children.
Prevenar 13 was initially licensed for the prevention of invasive disease, pneumonia and acute otitis media in children.

The approved indications for Prevenar 13 (pneumococcal polysaccharide conjugate vaccine) in adults have been expanded to include the prevention of pneumonia caused by Streptococcus pneumoniae, in addition to the prevention of invasive pneumococcal disease. 

Data to support licensing for the new indication were provided by the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), a double-blind, single-center trial in 84,496 adults aged 65 years or older who were randomly assigned to receive a single dose of either Prevenar 13 or placebo.

Further information
View Prevenar 13 drug record 
Summary of Product Characteristics
Manufacturer: Pfizer Ltd

Participants vaccinated with Prevenar 13 experienced 45.6% fewer first episodes of vaccine-type community-acquired pneumonia (CAP; primary endpoint) than those who received placebo (p=0.0006).

In terms of secondary endpoints, there were 45.0% fewer first episodes of non-bacteraemic/non-invasive vaccine-type CAP (p=0.0067) and 75.0% fewer first episodes of vaccine-type invasive pneumococcal disease (p=0.0005) in the Prevenar 13 group than the placebo group.

Additional data showed reductions in vaccine-type CAP, non-bacteraemic/non-invasive vaccine-type CAP, and vaccine-type invasive pneumococcal disease for up to 4 years after Prevenar 13 vaccination.

The safety profile of Prevenar 13 was consistent with that observed in previous studies in adults.

Results of CAPiTA were presented during the late-breaker session at the 9th International Symposium on Pneumococci and Pneumococcal Diseases in Hyderabad, India, on March 12, 2014.

 


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.